SPOTLIGHT: VCs back Caprotec


Berlin-based startup Caprotec Bioanalytics GmbH has rounded up $8.8 million in two rounds of financing from Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds and private investors for further development and marketing of its platform technology for analyzing complex protein mixtures. Release

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.